Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer

M. S. Soloway, M. Ikard, K. Ford

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Twenty-seven consecutive patients with locally extensive or metastatic urothelial cancer, primarily bladder, were given cis-diamminedichloroplatinum (II) (DDP) at a dose of 70 mg/m2 every three weeks. All patients had hydration and mannitol-induced diuresis initiated before administration of DDP. Nine patients (33%) had a partial response; 12 (45%) remained stable for an average duration of six months. Responders had a significantly greater survival than nonresponders. Although severe nephrotoxicity did not occur, patients with either a solitary or obstructed kidney were at greater risk of an increase in the serum creatinine during therapy.

Original languageEnglish
Pages (from-to)476-480
Number of pages5
JournalCancer
Volume47
Issue number3
StatePublished - Jan 1 1981
Externally publishedYes

Fingerprint

Cisplatin
Neoplasms
Diuresis
Mannitol
Urinary Bladder Neoplasms
Creatinine
Kidney
Survival
Serum
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Soloway, M. S., Ikard, M., & Ford, K. (1981). Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. Cancer, 47(3), 476-480.

Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. / Soloway, M. S.; Ikard, M.; Ford, K.

In: Cancer, Vol. 47, No. 3, 01.01.1981, p. 476-480.

Research output: Contribution to journalArticle

Soloway, MS, Ikard, M & Ford, K 1981, 'Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer', Cancer, vol. 47, no. 3, pp. 476-480.
Soloway, M. S. ; Ikard, M. ; Ford, K. / Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. In: Cancer. 1981 ; Vol. 47, No. 3. pp. 476-480.
@article{22f7a4de50944df0865d9a4483a7031f,
title = "Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer",
abstract = "Twenty-seven consecutive patients with locally extensive or metastatic urothelial cancer, primarily bladder, were given cis-diamminedichloroplatinum (II) (DDP) at a dose of 70 mg/m2 every three weeks. All patients had hydration and mannitol-induced diuresis initiated before administration of DDP. Nine patients (33{\%}) had a partial response; 12 (45{\%}) remained stable for an average duration of six months. Responders had a significantly greater survival than nonresponders. Although severe nephrotoxicity did not occur, patients with either a solitary or obstructed kidney were at greater risk of an increase in the serum creatinine during therapy.",
author = "Soloway, {M. S.} and M. Ikard and K. Ford",
year = "1981",
month = "1",
day = "1",
language = "English",
volume = "47",
pages = "476--480",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer

AU - Soloway, M. S.

AU - Ikard, M.

AU - Ford, K.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - Twenty-seven consecutive patients with locally extensive or metastatic urothelial cancer, primarily bladder, were given cis-diamminedichloroplatinum (II) (DDP) at a dose of 70 mg/m2 every three weeks. All patients had hydration and mannitol-induced diuresis initiated before administration of DDP. Nine patients (33%) had a partial response; 12 (45%) remained stable for an average duration of six months. Responders had a significantly greater survival than nonresponders. Although severe nephrotoxicity did not occur, patients with either a solitary or obstructed kidney were at greater risk of an increase in the serum creatinine during therapy.

AB - Twenty-seven consecutive patients with locally extensive or metastatic urothelial cancer, primarily bladder, were given cis-diamminedichloroplatinum (II) (DDP) at a dose of 70 mg/m2 every three weeks. All patients had hydration and mannitol-induced diuresis initiated before administration of DDP. Nine patients (33%) had a partial response; 12 (45%) remained stable for an average duration of six months. Responders had a significantly greater survival than nonresponders. Although severe nephrotoxicity did not occur, patients with either a solitary or obstructed kidney were at greater risk of an increase in the serum creatinine during therapy.

UR - http://www.scopus.com/inward/record.url?scp=0019352425&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019352425&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 476

EP - 480

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -